State Street Corporation filed a Schedule 13G with the SEC on November 10, 2026, disclosing a beneficial ownership position in DexCom Inc common stock as of the event date of September 30, 2026.
State Street Corporation filed a Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of 3,874,849 shares of Delek US Holdings Inc common stock as of September 30, 2026.
Legend Biotech Corporation filed a Form 6-K on November 10, 2026, furnishing unaudited interim condensed consolidated financial statements and management's discussion and analysis for the three and nine months ended September 30, 2026.
State Street Corporation filed a Schedule 13G with the SEC on November 10, 2026, disclosing beneficial ownership of approximately 5.2% of Dollar Tree Inc's common stock as of September 30, 2026.
Palladyne AI Corp. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 10, 2026, covering the fiscal quarter ended September 30, 2026.
State Street Corporation filed a Schedule 13G with the SEC on November 10, 2026, disclosing beneficial ownership of 6,158,254 shares of DuPont de Nemours Inc common stock as of September 30, 2026.
State Street Corporation filed a Schedule 13G with the SEC on November 10, 2026, disclosing beneficial ownership of 1,486,413 shares of Eagle Bancorp Inc common stock as of September 30, 2026.
Olema Pharmaceuticals, Inc. filed its Form 10-Q with the SEC on November 10, 2026, reporting unaudited financial results for the quarterly period ended September 30, 2026, under NASDAQ:OLMA.
City Therapeutics, Inc. filed a Current Report on Form 8-K on November 10, 2026, disclosing that it issued a press release announcing the first participant dosed in a Phase 1 clinical trial of CITY-RBP4 for the treatment of Stargardt disease.
Scholar Rock Holding Corporation filed a Form 8-K on November 10, 2026, disclosing that its subsidiary Scholar Rock Inc. entered into an asset purchase agreement to sell a Rare Pediatric Disease Priority Review Voucher to BioNTech US Inc. for $205 million in cash, and …